JNJ 0966

Pricing Availability   Qty
Description: Pro-MMP9 activation inhibitor
Chemical Name: N-[2-[(2-Methoxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]acetamide
Purity: ≥98% (HPLC)
Datasheet
Citations
Reviews
Literature (1)

Biological Activity for JNJ 0966

JNJ 0966 is a pro-MMP9 activation inhibitor (IC50 = 440 nM). Inhibits the conversion of pro-MMP9 to active MMP9, without directly affecting MMP9 enzymatic activity. Exhibits selectivity for pro-MMP9 over pro-MMP1, 2 and 3. Inhibits cell invasion in in vitro assays. Reduces motor impairment in a mouse EAE model. Brain penetrant.

Compound Libraries for JNJ 0966

JNJ 0966 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.

Technical Data for JNJ 0966

M. Wt 360.45
Formula C16H16N4O2S2
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 315705-75-0
PubChem ID 1117189
InChI Key ZADCDCMLLGDCRM-UHFFFAOYSA-N
Smiles COC1=C(C=CC=C1)NC2=NC(C3=C(N=C(S3)NC(C)=O)C)=CS2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for JNJ 0966

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 18.02 50

Preparing Stock Solutions for JNJ 0966

The following data is based on the product molecular weight 360.45. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.5 mM 5.55 mL 27.74 mL 55.49 mL
2.5 mM 1.11 mL 5.55 mL 11.1 mL
5 mM 0.55 mL 2.77 mL 5.55 mL
25 mM 0.11 mL 0.55 mL 1.11 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

References for JNJ 0966

References are publications that support the biological activity of the product.

Scannevin et al (2017) Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation. J.Biol.Chem. 292 17963 PMID: 28860188


If you know of a relevant reference for JNJ 0966, please let us know.

View Related Products by Product Action

View all Matrix Metalloprotease Inhibitors

Keywords: JNJ 0966, JNJ 0966 supplier, JNJ0966, Pro-MMP9, activation, inhibitor, zymogen, MMP9, signaling, brain, penetrant, cell, invasion, EAE, experimental, autoimmune, encephalomyelitis, matrix, metalloprotease, Matrix, Metalloprotease, 6439, Tocris Bioscience

Citations for JNJ 0966

Citations are publications that use Tocris products.

Currently there are no citations for JNJ 0966. Do you know of a great paper that uses JNJ 0966 from Tocris? Please let us know.

Reviews for JNJ 0966

There are currently no reviews for this product. Be the first to review JNJ 0966 and earn rewards!

Have you used JNJ 0966?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Angiogenesis in Cancer Poster

Angiogenesis in Cancer Poster

This poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.